Group 1 - Immunic, Inc. (NASDAQ:IMUX) has received a key patent from the European Patent Office for its lead asset, vidofludimus calcium, which is expected to provide protection in Europe until 2038, with potential extension to 2043 through a Supplementary Protection Certificate [1][2] - The patent claims cover vidofludimus and its various forms, ensuring broad protection across all label-relevant dosing regimens, not limited to a single formulation [2] - H.C. Wainwright has lowered its price target for Immunic, Inc. to $5 from $8 while maintaining a Buy rating, indicating a reassessment of the company's valuation [3]

Core Insights - Scinai Immunotherapeutics is expanding its capabilities through the acquisition of Recipharm Israel and is participating in BIO-Europe Spring® 2026 to showcase its integrated CDMO platform and immunology pipeline [1][2][8] CDMO Platform Expansion - The company’s CDMO subsidiary, Scinai Biopharma Services Ltd., will be represented at the conference, highlighting its role in supporting biotechnology and pharmaceutical companies from early development to commercialization [2][3] - Scinai's CDMO model is built on three strategic pillars: a cGMP biologics development and manufacturing site in Jerusalem, a cGMP small-molecule API development and manufacturing site in Yavne acquired from Recipharm, and a strategic commercial collaboration with Recipharm [4][5] Immunology Pipeline Development - Scinai is focusing on advancing its pipeline of antibody-based therapeutics targeting autoimmune and inflammatory diseases, particularly in dermatology, with assets licensed from the Max Planck Society, University Medical Center Göttingen, and PinCell S.r.l. [6][10] - The company is actively seeking strategic partnerships, co-development collaborations, and licensing opportunities to further advance its pipeline [7] Strategic Positioning - The CEO of Scinai emphasized the company's unique position to partner with biotech and pharma companies across the full lifecycle of their products, from early-stage development through clinical and commercial manufacturing [8]

Core Insights - Nektar Therapeutics will host an investor call and live webcast to discuss topline results from the 36-week maintenance period of the Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin, targeting moderate-to-severe atopic dermatitis on February 10, 2026 [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials: one for atopic dermatitis and another for alopecia areata, along with a Phase 2 trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3]

Core Insights - Windward Bio AG has announced a licensing agreement with Qyuns Therapeutics for the development and commercialization of WIN027, a bispecific antibody targeting TSLP and IL-13, which is expected to enhance treatment for advanced immunological diseases [1][2][3] Group 1: Licensing Agreement Details - The agreement grants Windward Bio exclusive rights to develop, manufacture, and commercialize WIN027 outside of China, with a total deal value of up to $700 million, including upfront payments, equity, and milestone payments contingent on specific achievements [2] - The licensing deal is part of Windward Bio's strategy to expand its immunology pipeline and accelerate the development of differentiated therapies for serious immunological diseases [3] Group 2: Product Information - WIN027 is a humanized IgG1 bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, designed for long-acting inhibition and less frequent dosing, targeting conditions such as asthma, COPD, and atopic dermatitis [4][7] - WIN378, another product in Windward Bio's pipeline, is a long-acting anti-TSLP monoclonal antibody currently in Phase 2 trials for asthma, with initial data expected in 2026 [3][5] Group 3: Market Opportunity - The combined market opportunity for WIN027 and WIN378 is estimated to exceed $50 billion, addressing significant unmet needs across a range of immunological diseases [3]